Opvee Spray
Product Images NDC 12496-0003

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Opvee (NDC 12496-0003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Indivior Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Opvee 01)

Chemical structure of nalmefene hydrochloride, the active ingredient in OPVEE nasal spray 2.7 mg/100uL by Indivior Inc. The diagram shows the molecular structure including rings, hydroxyl groups, and a cyclopropyl group.*

FDA Label Image

Figure 1 (Opvee 02)

A line graph depicting percent minute ventilation over time in minutes. The x-axis ranges from -15 to 20 minutes, and the y-axis shows percent minute ventilation from 20% to 140%. Data points show a decrease in ventilation approaching zero minutes followed by recovery and return near baseline, with error bars indicating variability at each time point.*

FDA Label Image

Figure 2 (Opvee 03)

A line graph depicting minute ventilation (L/min) over time (minutes) ranging from 0 to 20 minutes. The plot shows an increasing trend in minute ventilation starting from 10 L/min at time zero, rising to about 17.5 L/min by 20 minutes, with error bars indicating variability at each time point.*

FDA Label Image

Figure 3 (a) (Opvee 04)

A line chart showing nalmefene plasma concentration (ng/mL) over 12 hours postdose. It compares two administration routes: 2.7 mg intranasal (IN) and 1.0 mg intramuscular (IM). The IN route shows higher initial plasma concentrations that decline over time, while the IM route has consistently lower plasma levels throughout the observed period.*

FDA Label Image

Figure 3 (b) (Opvee 05)

A line graph showing nalmefene plasma concentration (ng/mL) over time (minutes postdose) comparing 2.7 mg intranasal (IN) and 1.0 mg intramuscular (IM) administrations. The graph presents mean concentration values with error bars indicating variability at each time point up to 60 minutes.*

FDA Label Image

Figure 4 (a) (Opvee 06)

A line chart depicting nalmefene plasma concentration (ng/mL) over 12 hours postdose for three nalmefene hydrochloride nasal spray doses: 2.7 mg (one spray in one nostril), 5.4 mg (one spray in each nostril), and 5.4 mg (two sprays in one nostril). Concentrations peak early and decline over time.*

FDA Label Image

Figure 4 (b) (Opvee 07)

A line graph showing nalmefene plasma concentration (ng/mL) over 60 minutes postdose. It compares three dosing regimens: 2.7 mg one spray in one nostril, 5.4 mg one spray in each nostril, and 5.4 mg two sprays in one nostril, indicating concentration levels and variability over time.*

FDA Label Image

Figure (Opvee 08)

Packaging label of OPVEE nasal spray 2.7 mg/100uL by Indivior Inc. The image shows a white nasal spray unit with printed text including the proprietary name OPVEE, dosage strength 2.7 mg, and administration route NASAL SPRAY. The label is primarily white with black text.*

FDA Label Image

Figure A (Opvee 09)

An instructional illustration depicting a person administering rescue breaths (mouth-to-mouth resuscitation) to an unconscious individual lying on the ground, accompanied by the text 'Wake Up!' indicating the intent to rouse the person.*

FDA Label Image

Figure B (Opvee 10)

An instructional line drawing showing a person holding a small rectangular packet labeled OPVEE, with one hand peeling back the top corner to open it. The packet appears to contain a single-use nasal spray device, demonstrating how to open the packaging before use.*

FDA Label Image

Figure C (Opvee 11)

An instructional line drawing showing a hand holding a nasal spray device labeled with parts: nozzle and plunger, indicating how to position the spray for use.*

FDA Label Image

Figure D (Opvee 12)

An instructional illustration showing a hand administering a nasal spray to a person lying down. The spray is directed into the person's nostril, demonstrating the proper technique for using a nasal spray product.*

FDA Label Image

Figure E (Opvee 13)

An instructional black-and-white illustration showing a person's hand holding a smartphone with the screen displaying 'CALL 911'. Another hand is about to tap the call icon. This image likely emphasizes the importance of emergency response.*

FDA Label Image

Figure F (Opvee 14)

An instructional illustration showing a person lying on their side with the knee positioned to prevent rolling onto the stomach, and one hand supporting the head. This demonstrates a stable recovery position technique for patient safety.*

FDA Label Image

Figure G (Opvee 15)

An illustration of a clock face showing the time at 12:00 with a shaded segment indicating a 2 to 5 minute wait period. The text above the clock reads, "Wait 2 to 5 minutes." This image likely serves as an instructional guide for timing related to product use.*

FDA Label Image

Image (Opvee 16)

An instructional illustration showing a person performing chest compressions on a lying individual, with the text 'Wake Up!' displayed to indicate an emergency response scenario.*

FDA Label Image

Image (Opvee 17)

Instructional illustrations showing the use of OPVEE nasal spray. The first image depicts a person holding the OPVEE spray packaging near their upper arm. The second image shows a hand holding the nasal spray device, highlighting the nozzle and plunger components.*

FDA Label Image

Image (Opvee 18)

An instructional black-and-white line drawing showing a person lying down with their head tilted back while a hand administers a nasal spray into the person's nostril. This illustration depicts the proper technique for using the OPVEE nalmefene hydrochloride nasal spray.*

FDA Label Image

Image (Opvee 19)

An instructional illustration split into two panels: the left panel shows hands holding a smartphone with a prompt to call 911, and the right panel depicts a person lying on their side with instructions indicating the knee stops the body from rolling onto the stomach and the hand supports the head.*

FDA Label Image

Image (Opvee 20)

An instructional illustration showing a clock face with the time set at approximately 12:02. Text above the clock instructs to wait 2 to 5 minutes, indicating a recommended waiting period.*

FDA Label Image

Principal Display Panel (2.7 mg Bottle Carton)

OPVEE (nalmefene) Nasal Spray 2.7 mg carton packaging label. The label states it is for nasal use only and is manufactured by Indivior Inc. It contains two unit-dose nasal spray devices delivering 2.7 mg nalmefene per dose for opioid overdose treatment in adults and children 12 years and older. The label includes usage instructions, warnings, and storage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.